Fortrea will announce Q2 2025 financial results on August 6, hosting a conference call at 8:00 am ET.
Quiver AI Summary
Fortrea, a prominent global contract research organization, announced that it will release its second quarter 2025 financial results on August 6, 2025, prior to the market opening. The company will host a conference call at 8:00 am ET on the same day to discuss these results and will include a question-and-answer session. Interested participants can register online via Fortrea's Investor Relations website, with a recommendation to join the call at least 10 minutes early to avoid delays. A replay of the call will also be available shortly after the event. Fortrea specializes in clinical development solutions for the life sciences sector, offering extensive services across various therapeutic areas and emphasizing innovation in healthcare.
Potential Positives
- Fortrea is set to release its second quarter 2025 financial results, providing stakeholders with timely and relevant financial information.
- The scheduled conference call indicates a commitment to transparency and investor engagement, allowing for direct communication between the company and its investors.
- The press release emphasizes Fortrea's extensive experience and global presence in clinical development solutions, reinforcing its position as a leader in the CRO industry.
- Fortrea’s involvement in driving healthcare innovation highlights its role in supporting the advancement of life-changing therapies, which can attract interest from potential partners and clients.
Potential Negatives
- None
FAQ
When will Fortrea release its second quarter 2025 financial results?
Fortrea will release its second quarter 2025 financial results before the market opens on August 6, 2025.
How can I participate in the Fortrea earnings call?
Participants can register online at the Fortrea Investor Relations website to join the earnings call.
What time is the Fortrea conference call scheduled?
The Fortrea conference call is scheduled for 8:00 am ET on August 6, 2025.
Is there a way to access a replay of the earnings call?
A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website.
What services does Fortrea offer in the life sciences industry?
Fortrea provides clinical trial management, clinical pharmacology, and consulting services across multiple therapeutic areas.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FTRE Insider Trading Activity
$FTRE insiders have traded $FTRE stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $FTRE stock by insiders over the last 6 months:
- JILL G. MCCONNELL (Chief Financial Officer) has made 0 purchases and 5 sales selling 6,101 shares for an estimated $47,682.
- MARK A. MORAIS (Chief Operating Officer) has made 0 purchases and 5 sales selling 6,033 shares for an estimated $47,400.
- JAMES S. HANSON (General Counsel) has made 0 purchases and 2 sales selling 3,198 shares for an estimated $18,904.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FTRE Hedge Fund Activity
We have seen 164 institutional investors add shares of $FTRE stock to their portfolio, and 169 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PACER ADVISORS, INC. removed 4,913,949 shares (-81.2%) from their portfolio in Q1 2025, for an estimated $37,100,314
- MORGAN STANLEY added 4,370,497 shares (+418.4%) to their portfolio in Q1 2025, for an estimated $32,997,252
- MILLENNIUM MANAGEMENT LLC added 2,881,461 shares (+466.4%) to their portfolio in Q1 2025, for an estimated $21,755,030
- FMR LLC removed 2,834,166 shares (-35.0%) from their portfolio in Q1 2025, for an estimated $21,397,953
- BECK MACK & OLIVER LLC removed 2,700,885 shares (-47.9%) from their portfolio in Q1 2025, for an estimated $20,391,681
- STARBOARD VALUE LP removed 2,210,000 shares (-29.6%) from their portfolio in Q1 2025, for an estimated $16,685,500
- SESSA CAPITAL IM, L.P. removed 1,964,494 shares (-29.5%) from their portfolio in Q1 2025, for an estimated $14,831,929
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FTRE Analyst Ratings
Wall Street analysts have issued reports on $FTRE in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Underweight" rating on 05/13/2025
To track analyst ratings and price targets for $FTRE, check out Quiver Quantitative's $FTRE forecast page.
$FTRE Price Targets
Multiple analysts have issued price targets for $FTRE recently. We have seen 4 analysts offer price targets for $FTRE in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Ann Hynes from Mizuho set a target price of $7.0 on 07/11/2025
- Elizabeth Anderson from Evercore ISI Group set a target price of $5.0 on 07/09/2025
- Matthew Sykes from Goldman Sachs set a target price of $5.0 on 05/14/2025
- Luke Sergott from Barclays set a target price of $5.0 on 05/13/2025
Full Release
DURHAM, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.
To participate in the earnings call, participants should register online at the Fortrea Investor Relations website . To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link .
A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea Investor Relations website.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts
Hima Inguva (Investors) – 877-495-0816, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
